Rapid identification of 6328 isolates of pathogenic yeasts using MALDI-ToF MS and a simplified, rapid extraction procedure that is compatible with the Bruker Biotyper platform and database

Medical Mycology

Volumn 54, Issue 1, 2016, Pages 80-88

  Fraser, Mark ^a   Brown, Zoe ^a   Houldsworth, Marian ^a   Borman, Andrew M ^a   Johnson, Elizabeth M ^a  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

Candida species; MALDI ToF MS; Pathogenic yeasts; Rapid extraction method; Rapid identification

Indexed keywords

CANDIDA; DATA BASE; EXTRACTION; FUNGAL CELL CULTURE; HUMAN VERSUS NONHUMAN DATA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SPECIES; CHEMISTRY; CLASSIFICATION; EVALUATION STUDY; HUMAN; ISOLATION AND PURIFICATION; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MYCOSIS; PROCEDURES; SPECIMEN HANDLING; TIME FACTOR; YEAST;

FUNGAL PROTEIN;

FUNGAL PROTEINS; HUMANS; MICROBIOLOGICAL TECHNIQUES; MYCOSES; SPECIMEN HANDLING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS; YEASTS;

EID: 84969711608     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myv085     Document Type: Article

References (50)

1. Marr KA. Invasive Candidainfections: the changing epidemiology. Oncology 2004; 14: 9-14.
2. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005; 41: 521-526.
3. Ruhnke M. Epidemiology of Candida albicansinfections and role of non-Candida albicansyeasts. Curr Drug Targets 2006; 7: 495-504.
4. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
5. Pfaller M, Neofytos D, Diekema D et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH AllianceR ®) registry, 2004-2008. Diagn Microbiol Infect Dis 2012; 74: 323-331.
6. Wright WL, Wenze RP. Nosocomial Candida. Epidemiology, transmission and prevention. Infect Dis Clin N Am 1997; 11: 411-425.
7. Borman AM, Linton CJ, Oliver D et al. Rapid molecular identification of pathogenic yeast species by Pyrosequencing® analysis of 35 nucleotides of the Internal Transcribed Spacer 2. J Clin Microbiol 2010; 48: 3648-3653.
8. Linton CJ, Borman AM, Cheung G et al. Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years' experience at the UK Mycology Reference Laboratory. J Clin Microbiol 2007; 45: 1152-1158.
9. Fromtling RA. Section VIII; Mycology. In Murray PR, Baron EJ, Jorgensen J, Pfaller MA, Landry ML. (eds.), Manual of Clinical Microbiology, 9th ed. Washington, DC: ASM press, 2007.
10. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
11. Wingard JR. Infections due to resistant Candidaspecies in patients with cancer who are receiving chemotherapy. Clin Infect Dis 1994; 19(suppl. 1): 49-53.
12. Snydman DR. Shifting patterns in the epidemiology of nosocomial Candidainfections. Chest 2003; 123: 500S-503S.
13. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
14. Morrell M, Fraser VJ, Kollef MH. Delaying empiric treatment of Candidabloodstream infection until positive blood culture results are obtained: a potential risk factor for mortality. Antimicrob Agents Chemother 2005; 49: 3640-3645.
15. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
16. Parkin MD, Sabuda DM, Elsayed S et al. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candidaspecies infections. J Antimicrob Chemother 2007; 60: 613-618.
17. Borman AM, Petch R, Linton CJ et al. Candida nivariensis, an emerging pathogenic fungus with multi-drug resistance to antifungal agents. J Clin Microbiol 2008; 46: 933-938.
18. Pfaller MA, Jones RN, Messer SA et al. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998; 31: 327-332.
19. Pfaller MA, Jones RN, Doern GV et al. International surveillance of blood stream infections due to Candidaspecies in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 1999; 35: 19-25.
20. Pfaller MA, Diekema DJ, Andes D et al. Clinical breakpoints for the echinocandins and Candidarevisited: integration of molecular, clinical, and microbiological data to arrive at speciesspecific interpretive criteria. Drug Resist Updat 2011; 14: 164-176.
21. Pfaller MA, Diekema DJ. Wild-type MIC distributions and epidemiological cutoff values for fluconazole and Candida: time for new clinical breakpoints? Curr Fungal Infect Rep 2010; 4: 168-174.
22. Pfaller MA, Andes D, Arendrup MC et al. Clinical breakpoints for voriconazole and Candidaspp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011; 70: 330-343.
23. Pfaller MA, Boyken L, Hollis RJ et al. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candidaspp. as determined by 24-hour CLSI broth microdilution. J Clin Microbiol 2011; 49: 630-637.
24. Pfaller MA, Castanheira M, Diekema DJ et al. Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J Clin Microbiol 2011; 49: 3800-3804.
25. Bhally HS, Jain S, Shields C et al. Infection in a neonate caused by Pichia fabianii: importance of molecular identification. Med Mycol 2006; 44: 185-187.
26. Borman AM, Linton CJ, Oliver D et al. Pyrosequencing® analysis of 20 nucleotides of the Internal Transcribed Spacer 2 discriminates Candida parapsilosis, Candida metapsilosis and Candida orthopsilosis. J Clin Microbiol 2009; 47: 2307-2310.
27. Borman AM, Szekely A, Linton CJ et al. Epidemiology, antifungal susceptibility and pathogenicity of Candida africanaisolates from the United Kingdom. J Clin Microbiol 2013; 51: 967-972.
28. Boyanton BL, Luna RA, Fasciano LR et al. DNA pyrosequencing-based identification of pathogenic Candida species by using the internal transcribed spacer 2 region. Arch Pathol Lab Med 2008; 132: 667-674.
29. Gharizadeh B, Norberg E, Loffler J et al. Identification of medically important fungi by the Pyrosequencing technology. Mycoses 2004; 47: 29-33.
30. Montero CI, Shea YR, Jones PA et al. Evaluation of Pyrosequencing® technology for the identification of clinically relevant non-dematiaceous yeasts and related species. Eur J Clin Microbiol Infect Dis 2008; 27: 821-830
31. Stevenson LG, Drake SK, Shea YR et al. Evaluation of matrixassisted laser desorption ionization-time of flight mass spectrometry for identification of clinically important yeast species. J Clin Microbiol 2010; 48: 3482-3486.
32. Dhiman N, Hall L, Wohlfiel SL et al. Performance and cost analysis of matrix-assisted laser desorption ionization-time of flight mass spectrometry for routine identification of yeast. J Clin Microbiol 2011; 49: 1614-1616.
33. Pinto A, Halliday C, Zahra M et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry identification of yeasts is contingent on robust reference spectra. PLoS One 2011; 6: e25712.
34. Lacroix C, Gicquel A, Sendid B et al. Evaluation of two matrixassisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems for the identification of Candida species. Clin Microbiol Infect 2014; 20: 153-158.
35. Rosenvinge FS, Dzajic E, Knudsen E et al. Performance of matrix-assisted laser desorption-time of flight mass spectrometry for identification of clinical yeast isolates. Mycoses 2013; 56: 229-235.
36. Vleck A, Kolecka A, Khayhan K et al. Interlaboratory comparison of sample preparation methods, database expansions, and cut-off values for identification of yeasts by matrixassisted laser desorption ionisation time-of-flight mass spectrometry using a yeast test panel. J Clin Microbiol 2014; 52: 3023-3029.
37. De Carolis E, Vella A, Vaccaro L et al. Development and validation of an in-house database for matrix-assisted laser desorption ionisation time-of-flight mass spectrometry-based yeast identification using a fast protein extraction procedure. J Clin Microbiol 2014; 52: 1453-1458.
38. Gorton RL, Seaton S, Ramnarain P et al. Evaluation of a short, on-plate formic acid extraction method for matrix-assisted laser desorption ionisation time-of-flight mass spectrometry-based identification of clinically relevant yeast isolates. J Clin Microbiol 2014; 52: 1253-1255.
39. Goyer M, Lucchi G, Ducoroy P et al. Optimization of the preanalytical steps of matrix-assisted laser desorption ionization-time of flight mass spectrometry identification provides a flexible and efficient tool for identification of clinical yeast isolates in medical laboratories. J Clin Microbiol 2012; 50: 3066-3068.
40. Cassagne C, Cella AL, Suchon P et al. Evaluation of four pretreatment procedures for MALDI-TOF MS yeast identification in the routine clinical laboratory. Med Mycol 2013; 51: 371-377.
41. Pence MA, McElvania TeKippe E, Wallace MA et al. Comparison and optimisation of two MALDI-ToF MS platforms for the identification of medically relevant yeast species. Eur J Clin Microbiol Infect Dis 2014; 33: 1703-1712.
42. Borman AM, Fraser M, Linton CJ et al. An improved method for the preparation of total genomic DNA from isolates of yeast and mould using Whatman FTA filter papers. Mycopathologia 2010; 169: 445-449.
43. Kurtzman CP, Robnett CJ, Basehoar-Powers E. Phylogenetic relationships among species of Pichia, Issatchenkia and Williopsis determined from multigene sequence analysis, and the proposal of Barnettozymagen. nov., Lindneragen. nov. and Wickerhamomycesgen. nov. FEMS Yeast Res 2008; 8: 939-954.
44. Kurtzman CP. Recognition of yeast species from gene sequence comparisons. Open Appl Informatics J2011; 5(S1-M4): 20-29.
45. Groenewald M, Coutinho T, Smith MT et al. Species reassignment of Geotrichum byndzae, Geotrichum phurueaensis, Geotrichum silvicolaand Geotrichum vulgarebased on phylogenetic analyses and mating compatibility. Int J Syst Evol Microbiol 2012; 62: 3072-3080.
46. Yang S, Jin Y, Zhao G et al. Improvement of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinically important Candidaspecies. Clin Lab 2014; 60: 37-46.
47. Borman AM, Szekely A, Palmer MD et al. An assessment of the accuracy of identification of pathogenic yeasts in microbiology laboratories in the UK. J Clin Microbiol 2012; 50: 2639-2644.
48. Bernhard M, Weig M, Zautner AE et al. Yeast on-target lysis (YOTL), a procedure for making auxiliary mass spectrum data sets for clinical routine identification of yeasts. J Clin Microbiol 2014; 52: 4163-4167.
49. Pence MA, McElvania TeKippe E, Wallace MA et al. Comparison and optimization of two MALDI-ToF MS platforms for the identification of medically relevant yeast species. Eur J Clin Microbiol Infect Dis 2014; 33: 1703-1712.
50. Westblade LF, Jennemann R, Branda JA et al. Multicenter study evaluating the Vitek MS system for identification of medically important yeasts. J Clin Microbiol 2013; 51: 2267-2272